Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPD-101 placebo-controlled 52-week COPD exacerbation study
2026-525216-34-00Phase 2Authorised
- Sponsor
- Expedition Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of XH-S004 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Expedition Therapeutics. Primary endpoints: Annualized rate of moderate and severe COPD exacerbations and Safety and tolerability. Planned start Sep 2026; status: authorised.
02
Drugs
XH-S004
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2026-525216-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525216-34-00.